Overview

Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss

Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This study is an open label proof of concept study of rilonacept for patients with ANSHL
Phase:
Early Phase 1
Details
Lead Sponsor:
Stanley Cohen
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Rilonacept